Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a... Read More

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update. Highlights from the first six months of 2025 included the following: Total revenues for the second... Read More

Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company’s commercial functions, including sales, marketing, and market... Read More

Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will... Read More

Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz ® and RhodoLED ® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG. Under their new agreement, the effective royalty rate paid by Biofrontera Inc. will be reduced to 12% (and 15% above revenue of $65 million) of net sales from 25% - 35% of net sales. This transaction, coupled with an $11 million... Read More

WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of Biofrontera AG on June 10, 2025, according to which the two companies are in negotiations regarding a possible combination of the two companies or an adjustment of the license and supply... Read More

Biofrontera received patent approval for the revised formulation of Ameluz ® in April 2025, extending patent protection through to December 2043. The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescription drug products, along with patent and exclusivity information. Inclusion signifies FDA recognition of the revised formulation's approved status and its intellectual... Read More

Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2025 and provided a business update. Highlights from the first quarter of 2025 and subsequent... Read More

Biofrontera has received patent approval for the revised formulation of Ameluz ® , which extends patent protection through to December 2043 Ameluz PDT offers the potential for effective treatment of moderate to severe acne without the side effects associated with some systemic therapies 4 Approximately 50 million people in the US are suffering from acne vulgaris, including both adolescents and adults 1,2 The US acne... Read More

WOBURN, MA / ACCESS Newswire / May 6, 2025 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025. The results will be released after the market close on Thursday, May 15 and the company will host a conference... Read More

The initiative is a social media challenge ahead of Global AK Awareness Day, on May 24, which supports the work of The Skin Cancer Foundation and Euromelanoma The Hats On Challenge provides an opportunity to take part in raising awareness of AK. Actinic Keratosis (AK) is a rough, scaly patch on the skin caused by years of sun exposure. If left untreated, AK can develop into squamous cell carcinoma, a type of skin cancer.... Read More

Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2024. Highlights from 2024 and subsequent weeks include: Reported record... Read More

First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremities Protocol involves one or two PDT treatments using 1-3 tubes of Ameluz ® or vehicle gel over a surface area of up to 240 cm 2 Treatment phase expected to be complete by Q3 2025 WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in... Read More

WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a... Read More

Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024. Data from follow-up will be included in FDA submission, expected in Q3 2025. Biofrontera announced highly statistically significant results for all primary and secondary endpoints (p <0.0001) in October 2024. BCC, of which sBCC is a subgroup, is the most common skin cancer in the US with more than 3 million cases each year 1 . WOBURN, Mass.,... Read More

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced it will be presenting at The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024 at the New York Athletic Club in New York... Read More

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders. The Note matures on November 22, 2027, bears a... Read More

● Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ● Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%. ●... Read More

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will... Read More

First Phase 3 PDT study in patients with sBCC in the United States. Primary and secondary endpoints all highly statistically significant p<0.0001 Correlates to data seen in Europe where sBCC is already incorporated in the Summary of Product Characteristics. BCC is the most common skin cancer in the US, with more than 3 million cases each year 1 . WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:... Read More

First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions. Data now being analyzed, interim results expected November 2024. BCC is the most common skin cancer in the US with more than 3 million cases each year 1 . WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the... Read More

Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz ® -PDT using the BF-RhodoLED or the RhodoLED XL lamp Supplemental New Drug Application (sNDA) supported by two Phase 1 safety studies AK is the second most common diagnosis made by dermatologists in the United States 1 An estimated 13 million treatments given each year for AK in the US 2 WOBURN, Mass., Oct. 07, 2024 (GLOBE... Read More

WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York, NY. Date: October 9, 2024 Time of Presentation: 12:30 - 1:10 PM ET Format: Live Presentation 1x1... Read More

Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update. Highlights from the second quarter of 2024 and subsequent weeks included the following: Total revenues for the second quarter of... Read More

WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024. The results will be released after the market close on Wednesday, Aug 14 and the company will host a conference call on Thursday, August... Read More

Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2024 and provided a business update. Highlights from the first quarter of 2024 and subsequent weeks... Read More

WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 29, 2024 on Wednesday, May 15, 2024. The results will be released after the market close on Wednesday, May 15 and the company will host a conference call on Thursday, May 16... Read More

WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that its 2024 Annual Meeting of Stockholders will be held on June 12, 2024 and that the close of business on April 22, 2024 will be the record date for the determination of stockholders entitled to notice of and to vote at... Read More

Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2023. Highlights from 2023 and subsequent weeks include: Record total revenues of... Read More

Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2023. Highlights from 2023 and subsequent weeks include: Record total revenues of... Read More

WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2023 on Friday, March 15, 2024. The results will be released after the market close on Friday, March 15 and the company will host a conference call on Monday,... Read More

Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth WOBURN, MA / ACCESSWIRE / February 23, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the... Read More

Ameluz ® transfer price to Biofrontera AG reduced significantly Control of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1 WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced the restructuring of agreements between the Company and its... Read More

Company secures financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the... Read More

WOBURN, MA / ACCESSWIRE / October 31, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatologic products, entered into a securities purchase agreement with a certain institutional investor, pursuant to which the Company agreed to issue and sell to the investor an aggregate of 1,205,000 shares of its common stock (or common stock... Read More

WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and... Read More

Trial Results Expected in Mid-2024 WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces that patient enrollment is now complete in the Phase 3 clinical study evaluating Ameluz ® -PDT in combination with the BF-RhodoLED ® lamp for the treatment of basal cell carcinoma (BCC). This study... Read More

WOBURN, MA / ACCESSWIRE / June 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces its sponsorship of The Sun Bus , a mobile classroom and clinic bringing free skin cancer screenings and public education to communities across the U.S. The 2023 tour kicked off in March in Colorado and continues through... Read More

WOBURN, MA / ACCESSWIRE / May 30, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that its Board of Directors has named Hermann Luebbert as Chief Executive Officer. Mr. Luebbert is a founder of the Company and currently serves as Executive Chairman. He will continue to serve as Chairman of the Board... Read More

Novel Protocol is Expected to be Less Painful with Efficacy Similar to Conventional PDT WOBURN, MA / ACCESSWIRE / May 15, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that the U.S. Patent and Trademark Office (USPTO) has granted a new patent to Biofrontera Bioscience GmbH related to a photodynamic therapy (PDT)... Read More

WOBURN, MA / ACCESSWIRE / May 11, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it has entered into a $6.5 million secured line of credit with MidCap Business Credit, LLC, subject to the borrowing base formula, minimum excess availability and other terms and conditions. "Biofrontera has significant growth potential and... Read More

WOBURN, MA / ACCESSWIRE / April 28, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 31, 2023 on Friday, May 12, 2023. The results will be released before the market opens and the company will host a conference call at 8:30AM Eastern Time. Conference call:... Read More

WOBURN, MA / ACCESSWIRE / April 26, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that that the last patient in a Phase I study to evaluate the safety and tolerability of Ameluz ® - PDT for treatment of mild to severe actinic keratosis on the face and scalp in the expanded treatment field using 3 tubes of BF-200 ALA 10% gel... Read More

WOBURN, MA / ACCESSWIRE / March 27, 2023 / Biofrontera Inc. (NASDAQ:BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it is executing on the company's stated plans to invest in and meaningfully grow its' salesforce in 2023. "With this investment in the salesforce, Biofrontera is taking an important step forward in our growth strategy," stated Erica... Read More

Providing live demonstrations of a PDT procedure using the RhodoLED ® lamp at booth #2224 WOBURN, MA / ACCESSWIRE / March 17, 2023 / Biofrontera Inc. (NASDAQ:BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will be hosting a booth showcasing its innovative, FDA-approved products at the 2023 American Academy of Dermatology (AAD) Annual Meeting taking... Read More

WOBURN, MA / ACCESSWIRE / March 9, 2023 / Biofrontera, Inc. (NASDAQ:BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and twelve months ended December 31, 2022. Highlights Record 2022 annual Ameluz ® revenues were 12% higher than previous record in pre-COVID 2019 Grew share in our target market in 2022 by about 12% Total... Read More

WOBURN, MA / ACCESSWIRE / March 2, 2023 / Biofrontera, Inc. (NASDAQ:BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products will be presenting at the 35 th Annual ROTH Conference in Laguna Nigel, CA being held March 12-14, 2023. Biofrontera, Inc. Chief Executive Officer, Erica Monaco, and Chief Financial Officer, Fred Leffler will represent the company at the conference. The... Read More

WOBURN, MA / ACCESSWIRE / February 22, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2022 on Wednesday, March 8, 2023. The results will be released after the market close and the company will host a conference call at 4:30PM Eastern Time.... Read More

WOBURN, MA / ACCESSWIRE / February 15, 2023 / Biofrontera, Inc. (NASDAQ:BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21 st - 24 th , 2023. Biofrontera, Inc. Chief Executive Officer, Erica Monaco, and Chief Financial... Read More

WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the first patient has been dosed in a Phase 3 randomized, double-blind, vehicle-controlled, multicenter clinical study to evaluate the safety and efficacy of Ameluz ® and BF-RhodoLED ® XL in the field-directed treatment of actinic... Read More

WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and 12 months ended December 31, 2022. Revenues for the fourth quarter of 2022 are anticipated to be in the range of approximately $10.2 million to $10.4 million, an increase of approximately 12%... Read More

WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results from its 2022 Annual Meeting of Stockholders held on December 12, 2022. Stockholders re-elected board nominee Loretta M. Wedge to the Biofrontera Inc. Board of Directors as Class I director to serve until the... Read More